Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04728230
Title Olaparib and Durvalumab With Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, PRIO Trial
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center

lung small cell carcinoma


Carboplatin + Durvalumab + Etoposide + Olaparib

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.